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Abstract
Background: Scleroderma is an antigen-driven T cell-mediated autoimmune disease. Presence of anti-topoisomerase-I
antibodies is associated with pulmonary fibrosis and predicts increased mortality. Characterization of autoreactive T
lymphocytes may shed light on disease pathogenesis and serve as a biomarker for disease activity. Here, we aimed to
quantify and functionally characterize circulating topoisomerase I (topo-I)-specific CD4+ T cells and to define their
association with presence and progression of interstitial lung disease (ILD) in patients with scleroderma.
Methods: Using flow cytometry, circulating topo-I-reactive CD4+ T cells were identified by the expression of specific
activation markers (CD154 and CD69) upon stimulation with purified topo-I and quantified in 27 SSc patients and 4
healthy donors (HD). Polarization of autoreactive T cells (Th1, Th2, Th17, Th1–17) was defined using surface expression
of specific chemokine receptors. Presence and progression of ILD were determined using high-resolution chest CT
and pulmonary function tests.
Results: Topo-I-reactive CD4+ T cells were found in all topo-I-positive patients compared to one topo-I-negative
subject and no HD. Topo-I-specific CD4+ T cells exhibited a distinct Th17 polarized phenotype. Autoreactive T cells
were significantly increased in subjects with evidence of ILD and were quantitatively associated with the decline of
lung volumes.
Conclusions: Topo-I-specific T cells can be reliably quantified in the peripheral blood of patients with scleroderma,
exhibit a pro-inflammatory Th17 phenotype, and predict progression of ILD.
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Background
Systemic sclerosis (SSc) is characterized by obliterative
microangiopathy, progressive fibrosis of affected organs,
and autoimmunity [1]. Early in the disease, an inflamma-
tory mononuclear cell infiltrate precedes fibrosis and
parallels the development of vasculopathy in affected tis-
sues, suggesting that a disrupted immune response is a
major driver in SSc pathogenesis [2]. A more precise un-
derstanding of the immune effector pathways would
allow identifying reliable markers to monitor disease ac-
tivity and to define suitable targets for a selective thera-
peutic intervention.
In scleroderma, the presence of specific autoantibodies
is strongly associated with distinct clinical phenotypes
[3]. In particular, anti-topoisomerase-I (topo-I) anti-
bodies have high specificity for scleroderma, and are
present in 20–45 % of patients [4, 5]. They are associ-
ated with diffuse skin involvement and pulmonary fibro-
sis, and independently predict more severe disease and
mortality [6, 7]. Despite these robust associations, the
serum anti-topo-I antibody levels are not useful to
monitor disease activity and progression in SSc patients
[8–10], and there are no convincing data supporting a
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direct role for these autoantibodies in the pathogenesis
of SSc suggesting that the anti-topo-I response is in-
volved but not antibody mediated.
Importantly, anti-topo-I antibodies undergo class
switching and exhibit a strong association with human
leukocyte antigen (HLA) alleles across different ethnic
groups, implicating T cells in this response [11, 12]. The
presence of an antigen-driven, T cell-dependent process
in SSc is supported by several studies [12–16]. Defining
the functional phenotype of topo-I-reactive T cells would
be relevant to determine whether and how this cellular
subset may contribute to inflammation and tissue dam-
age in SSc. However, no conclusive data have been pro-
vided to define whether autoantigen-specific T cell
responses are amplified in individuals with active disease
and contribute to the generation of distinct phenotypes
through their effector function. These aspects have been
difficult to investigate due to poor accessibility of target
tissues and technical challenges to detect ex vivo low-
frequency antigen-specific T cells [12–16]. In this study,
we employed a novel assay to identify, quantify and
functionally characterize topo-I-specific CD4+ T cells.
This is based on the detection upon antigen stimulation
of reliable markers of early activation (i.e., CD154,
CD69) as well as of T cell polarization. We found that
topo-I-responsive T cells are selectively increased in
anti-topo-I-positive SSc patients and exhibit a T helper
(Th)17 pro-inflammatory functional phenotype, with fre-
quency quantitatively associated with presence and pro-
gression of interstitial lung disease (ILD). These findings
implicate amplified topo-I-specific T cell responses in
the pathogenesis of SSc lung disease, and suggest that
they may be appropriate targets to monitor disease activ-
ity and predict outcome.
Methods
Patients evaluated at the Johns Hopkins Scleroderma
Center were included in the study after providing writ-
ten informed consent if they met the American College
of Rheumatology preliminary criteria for the classifica-
tion of SSc [17]. The Johns Hopkins institutional review
board approved the study.
Clinical phenotyping
Demographic and clinical data including age, sex, ethnicity,
smoking status, disease duration, scleroderma subtype,
specific organ involvement, use of immunosuppressive
agents, and autoantibody status were obtained at the time
of the visit. Severity of skin involvement was quantified
using the modified Rodnan skin score [18]. Pulmonary in-
volvement was determined based on abnormal pulmonary
function tests (PFT), including measurements of forced
vital capacity (FVC) and single-breath carbon monoxide
diffusing capacity (DLCO), calculated according to the
American Thoracic Society recommendations [19]. All
PFT data were standardized to same reference values
[20, 21]. Presence of ILD was confirmed by the detection
of established fibrotic lung changes on computerized tom-
ography of the chest. ILD progression was defined as %
change in FVC in the year preceding the test date or in
the subsequent 10 months in those patients for whom
follow-up data became available. Lung disease severity
was assessed using the Medsger severity scale [22].
T cell culture and stimulation
Peripheral blood mononuclear cells (PBMC) were iso-
lated from whole blood through density-gradient centri-
fugation (Ficoll-Paque Plus, GE Healthcare, Chicago, IL,
USA), resuspended in RPMI medium supplemented with
5 % autologous serum, 2 mM L-glutamine, 100 U/ml
penicillin, and 100 ug/ml streptomycin, transferred onto
a 96-well plate (1.5 × 106 cells/well) and cultured at 37 °C.
To prevent CD154 internalization, PBMCs were preincu-
bated with anti-human CD40 blocking antibody (1 ug/ml;
G28.5, BioLegend, San Diego, CA, USA) for 15 minutes.
Subsequently, cells were stimulated for 18 hours using
alternatively 1 ug/ml staphylococcal enterotoxin B (SEB)/
staphylococcal enterotoxin A (SEA), 15 ug/ml tetanus
toxoid (TT) (NIBSC), 17 ug/ml human recombinant
topoisomerase-I purified from baculovirus-infected insect
cells (GenScript Biotech Corp, Piscataway, NJ, USA),
18 ug/ml purified human recombinant (baculovirus)
protein arginine methyltransferase 6 (PRMT6) (Cayman
Chemicals, Ann Arbor, MI, USA) or human peptidyl argin-
ine deiminase type 4 (PAD4) (gift from Dr. Erika Darrah).
Flow cytometry
After stimulation and washings with PBS, cells were then
stained with Live/Dead Fixable Blue Dead Cell Stain Kit
(Molecular Probes, Eugene, OR, USA), BV510-conjugated
anti-CD3 (OKT3, BioLegend), Pacific Blue-conjugated
anti-CD4 (RPA-T4, BD Pharmingen Franklin Lakes, NJ,
USA), APC-H7-conjugated anti-CD8 (SK1, BD, Franklin
Lakes, NJ, USA), PE-conjugated anti-CD154 (TRAP1, BD
Pharmingen), APC-conjugated anti-CD69 (FN50, BD
Pharmingen), Alexa-fluor 488-conjugated anti-CXCR3
(TG1/CXCR3, BioLegend), PerCP-Cy5.5-conjugated anti-
CCR6 (TG7/CCR6, BioLegend), PE-Cy7-conjugated anti-
CCR4 (1G1, BD Pharmingen) antibodies, and flow
cytometry acquisition was performed on a FACSAria
(BD) instrument. Analysis was conducted using FlowJo
software (Tree Star Inc., Ashland, OR, USA).
Cytokine quantitation
Freshly isolated PBMCs were sorted according to the
surface expression of the chemokine receptors CCR6,
CXCR3, and CCR4 (Fig. 3a), resuspended in RPMI
medium supplemented with 10 % fetal bovine serum
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(FBS), 2 mM L-glutamine, 100 U/ml penicillin and 100
ug/ml streptomycin, and then stimulated with anti-CD3/
CD28 beads (Life Technologies, Carlsbad, CA, USA) at a
bead-to-cell ratio of 2:1 for 48 hours (37 °C). Superna-
tants were collected and stored at -80 °C. Quantitation
of interferon (IFN)γ, interleukin (IL)-4 and IL-17A was
performed in duplicate using DuoSet-ELISA kits (R&D
Systems, Minneapolis, MN, USA) according to manufac-
turer’s instructions.
RNA isolation and cDNA synthesis
Topo-I specific CD4+ T cells identified after 18 h stimu-
lation as described in the Methods section of the main
manuscript were sorted according to their chemokine
receptor expression pattern into 50 μl of RNA extraction
buffer (PicoPure RNA isolation kit, Arcturus Bioscience,
Inc., Mountain View, CA, USA), incubated at 42 °C for
30 min and centrifuged (800 × g) at RT for 2 min. The
supernatant was then collected in an RNase-free tube.
Subsequent column filtration, washing, and elution of
RNA from the columns were performed according to
section C of the PicoPure RNA isolation protocol
(Protocol for Use with CapSure Macro Laser Capture
Microscope Caps). RNA integrity numbers were measured
using Agilent RNA 600 Pico kit (Agilent Technologies,
Santa Clara, CA, USA). Single-strand cDNAs were synthe-
sized with the Superscript III first-strand cDNA synthesis
kit following the manufacturer’s protocol (Invitrogen, Life
Technologies, Waltham, MA, USA).
Pre-amplification and quantitative real-time polymerase
chain reaction (RT-qPCR)
TaqMan PreAmp Master Mix Kit was used for cDNA
preamplification (Applied Biosystems, Life Technologies,
Waltham, MA, USA) using pooled primer mixes (200
times dilution) of the predesigned TaqMan assays of
IL17A (Hs00174383_m1), IL4 (Hs00174122_m1), IFNG
(Hs00989291_m1) and endogenous control beta-actin
(4326315E). cDNAs were preamplified in an ABI 9700
Thermal Cycler using the program: 95 °C hold for
10 min, and then 14 cycles of denaturation at 90 °C for
15 sec and annealing and extension at 60 °C for 4 min.
The pre-amplification PCR products were immediately
diluted five times with molecular biology-grade water (5
PRIME, Gaithersbrug, MD, USA) and stored at -20 °C or
immediately processed for qPCR. Duplex qPCR assays
were performed on technical duplicates using a Fam-
labeled probe for each target gene and a Vic-labeled
probe for the endogenous control gene, along with Taq-
Man® Advanced Fast PCR Master Mix (Life Technology).
RT-qPCR reactions were run in a 7500 Fast TaqMan in-
strument using the program: 95 °C hold for 20 sec
followed by 40 cycles of denaturation at 95 °C for 3 sec
and annealing and extension at 60 °C for 30 sec.
Calculations of relative expression from Ct data were
carried out according to User Bulletin #2 for ABI Prism
7900 Sequence Detection System.
Enzyme-linked immunosorbent assay (ELISA)
Anti-topoisomerase-I antibody concentration was measured
in the serum of SSc patients using QUANTA Lite Scl70
enzyme-linked immunosorbent assay (Inova Diagnostics,
San Diego, CA, USA) according to the manufacturer’s
instructions.
Statistical analysis
Statistical analysis was performed using Prism 6.0 Software
for Macintosh (GraphPad Software, San Diego, CA, USA).
Differences between variables were determined using
Student t test and Wilcoxon rank-sum test for continuous
variables, and the χ2 or Fisher’s exact test for categorical
variables. Multiple comparisons were performed by ana-
lysis of variance (ANOVA) with Bonferroni correction for
normally distributed variables or Kruskal-Wallis and
Dunn’s test otherwise. Linear associations were analyzed
using Pearson correlation coefficient upon assessment for
Gaussian distribution with Shapiro-Wilk test. Throughout,
a two-tailed α of 0.05 was used.
Results
We studied 27 consecutive SSc patients: 15 anti-topo-I-
positive and 12 anti-topo-I-negative. The two groups
were similar with regards to the main demographic and
disease characteristics (Table 1). Consistent with previ-
ous studies, anti-topo-I positive patients exhibited a sig-
nificant higher prevalence of ILD (p = 0.005), worse
modified Rodnan Skin Score, and a trend for lower dif-
fusion capacity of lung for carbon monoxide (DLco).
CD154 and CD69 upregulation identifies topoisomerase-I-
reactive CD4+ T cells
In order to detect with reliability and specificity antigen-
specific T cells, we developed a flow cytometry-based
protocol measuring the expression of early activation
markers CD69 and CD154 on CD4+ T cells. First, we opti-
mized the assay using PBMCs obtained from a healthy
donor recently immunized with combined tetanus, diph-
theria, and pertussis (Tdap) vaccine. After stimulation for
18 hours with tetanus toxoid (TT) in the presence of anti-
CD40 blocking antibodies and 5 % autologous serum, a se-
lective upregulation of both CD69 and CD154 was de-
tected on CD4+ T cells (0.8 %), while no significant
response was observed in unstimulated cells (0.04 %) or
after exposure to a negative control protein (0.09 %)
(Fig. 1a). The gating strategy for this experiment is shown
in Additional file 1: Figure S1. This approach was then ap-
plied to SSc patients using the whole topo-I molecule puri-
fied from baculovirus-infected insect cells and two
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unrelated proteins for which no T cell autoreactivity
was expected in SSc (PRMT6 and PAD4) as negative
controls. A representative experiment is shown in
Fig. 1b. Topo-I-reactive CD154 + CD69 + CD4+ T cells
were specifically identified in topo-I-positive SSc pa-
tients, while no response was triggered by either
PRMT6 or PAD4.
Topoisomerase-I-specific CD4+ T cells are increased in
anti-topo-I-positive SSc patients
Next, we sought to define the magnitude of autoreactive
CD4+ T cell expansion in the peripheral blood of SSc
patients. CD4+ T cells from anti-topo-I-positive subjects
consistently exhibited a significant upregulation of CD69
and CD154 upon topo-I challenge compared to un-
stimulated cells and those from anti-topo-I-negative pa-
tients (Fig. 1c). Autoreactive CD154 + CD69 + CD4+
topo-I-specific T cells were found in all 15 topo-I-
positive patients compared to only one topo-I-negative
subject and no healthy donors (HD), with a frequency
ranging between 0.136 % and 0.417 % of total CD4+ T
cells (topo-I-positive vs topo-I-negative p < 0.001; topo-
I-positive vs HD p = 0.005; topo-I-negative vs HD p = ns)
(Fig. 2).
Recognition of topoisomerase-I by autoreactive CD4+ T
cells is HLA-DR restricted
As CD4 T cells recognize antigens in the context of
major histocompatibility complex (MHC) class II mole-
cules, we asked whether T cell response to topo-I was
MHC-restricted and in particular mediated by HLA-DR
alleles [23]. PBMCs from topo-I-positive patients were
stimulated with topo-I in presence of anti-HLA-DR
or -HLA-DP blocking antibodies. Positive responses to
topo-I were significantly decreased by HLA-DR blockade
(p = 0.013), while anti-HLA-DP antibodies did not impact
Table 1 Patient demographics and clinical characteristics
Variables SSc Patients Topo-I negative (N = 12) Topo-I positive (N = 15) P value§
Age (years)* 51.3 ± 9.6 55.1 ± 7.4 48.2 ± 10.3 .093
Female 21 (78) 9 (75) 12 (80) .557
Race
White 22 (81) 9 (75) 13 (87) .338
Black 5 (19) 3 (25) 2 (13)
Smoking status
Never 16 (62) 9 (82) 7 (47) .174
Past 1 (4) 0 (0) 1 (7)
Current 9 (34) 2 (18) 7 (47)
Diffuse SSc skin type 15 (56) 5 (42) 10 (67) .182
mRSS* (range 0–51) 7 ± 8 5 ± 9 9 ± 7 .037
SSc duration
RP onset*, years 11.1 ± 7.8 11.2 ± 7.3 10.9 ± 8.5 .516
1st non-RP symptom*, years 10.2 ± 7.1 11.0 ± 7.2 9.6 ± 7.3 .792
Lung severity score* (range 0–4) 1.2 ± 1.3 0.9 ± 1.5 1.5 ± 1.1 .168
FVC* (% predicted) 77.9 ± 14.7 81.4 ± 19.8 77.07 ± 11.1 .106
DLCO* (% predicted) 75.3 ± 16.6 83.8 ± 15.7 71.3 ± 17.3 .051
ILD† 11 (46) 1 (10) 10 (71) .005
eRVSP* 28.8 ± 12.5 32.5 ± 17.5 25.9 ± 5.9 .522
Autoantibody status
ACA 3 (11) 3 (25) 0 (0) .075
Anti-RNA-polymerase III 5 (21) 3 (25) 1 (8) .295
Immunosuppression (current)‡ 11 (41) 4 (33) 7 (47) .381
All values are given as number (%) unless otherwise specified. Frequencies (%) are calculated based on available data. SSc disease duration was calculated at the
time of serum sampling from the onset of RP or from the first non-RP symptom. Lung severity score is reported as previously defined by Medsger et al. [29]
ACA anticentromere antibody, DLCO, diffusion capacity of lung for carbon monoxide, eRVSP right ventricular systolic pressure estimated by echocardiography,
FVC forced vital capacity, ILD interstitial restrictive lung disease, mRSS modified Rodnan skin score, RP Raynaud’s phenomenon, SSc systemic sclerosis
*Mean ± SD
†The presence of ILD was defined by presence of fibrosis on computed tomography of the chest (CT chest was available in 10 topo-I-negative and 14 topo-I-positive subjects)
‡Use of immunosuppressants includes cyclophosphamide, mycophenolate, methotrexate, or prednisone
§P values were determined by Fisher’s exact test, Pearson chi-square, or the Wilcoxon rank-sum test, as appropriate
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Fig. 1 (See legend on next page.)
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T cell activation (Fig. 3), implicating that specific topo-I
epitopes presented to the T cell receptor (TCR) by HLA-
DR molecules can selectively induce and maintain auto-
reactive T helper immune responses.
Topoisomerase-I-specific CD4+ T cells exhibit a Th17
polarized phenotype
To characterize the functional properties of topo-I-
specific CD4+ T cells, we validated and employed an ap-
proach to identify polarized T helper subsets based on
the surface expression of specific chemokine receptors
[24]. Th1, Th2, Th17 and Th1-Th17 CD4+ T cells were
defined by different combinations of CXCR3, CCR6 and
CCR4 expression (Fig. 4a). After cell sorting and stimu-
lation of each individual subset with anti-CD3/CD28
beads, the production of specific cytokines was assessed
in the supernatants, confirming their polarized status
(Fig. 4b). CCR6 + CCR4 + CXCR3- T cells (Th17) select-
ively secreted IL-17A, CCR6 + CCR4-CXCR3+ T cells
(Th1–17) both IFNγ and IL-17A, CCR6-CCR4 +
CXCR3- T cells (Th2) exclusively IL-4 and CCR6-CCR4-
CXCR3+ T cells (Th1) mainly IFNγ. Based on these
findings, we found that CD4+ T cells responding to
topo-I stimulation, exhibited a distinct enrichment in
the Th17 subset (p < 0.001) compared to the total CD4+
population, while their Th1 polarization was decreased
(p = 0.002) (Fig. 4c). The frequency of Th2 and Th1–17
subsets did not differ between topo-I-specific and total
CD4+ T cells. To further test the specificity of these phe-
notypes, IFNγ, IL-4 and IL-17A mRNA expression was
quantified in topo-I-responsive T cells sorted according
to their polarized status. The cytokine specificity of
autoreactive polarized subsets was confirmed at the
transcriptional level (Fig. 4d). In particular, topo-I-
specific CCR6 + CCR4 + CXCR3-CD4+ T cells selectively
expressed IL-17A mRNA.
Topoisomerase-I specific CD4+ T cells are quantitatively
associated with presence and progression of ILD
Several studies have confirmed that anti-topo-I positivity
is significantly more prevalent among SSc patients with
pulmonary fibrosis and entails worse clinical outcome.
(See figure on previous page.)
Fig. 1 Detection of circulating topoisomerase-I-specific CD4+ T cells by CD154 and CD69 expression and upregulation. After incubation (15 min)
with anti-CD40 blocking antibodies, freshly isolated peripheral blood mononuclear cells (PBMCs) were stimulated for 18 h in presence of 5 %
autologous serum as indicated below. Gating was set on lymphocytes, singlets, live, CD3+ and CD4+ cells. Numbers in quadrants indicate the
percent (%) cells in the parent CD4+ population. a PBMCs from a healthy donor recently immunized with combined tetanus, diphtheria, and
pertussis (Tdap) vaccine were stimulated with PRMT6 (negative control), SEA + SEB (positive control) and tetanus toxoid (TT). b PBMCs from a
topo-I+ SSc patient were stimulated with PRMT6, PAD4 (negative controls), or topo-I. c Representative experiments on two anti-topo-I-negative
and two anti-topo-I-positive SSc patients. The gating strategy for this experiment is shown in Additional file 1: Figure S1. PRMT6 protein arginine
methyltransferase 6, PAD4 human peptidyl arginine deiminase type 4
Fig. 2 Increased frequencies of topoisomerase-I-specific CD4+ T cells
in the blood of anti-topo-I-positive SSc patients. Topo-I-specific CD4+
T cells frequency was measured in the peripheral blood of 15 anti-
topo-I-positive, 12 anti-topo-I-negative SSc patients, and 4 healthy
donors (HD). Values represent the percentage of CD154 + CD69+ cells
within the CD4+ population. To minimize any noise from the background,
the frequency of topo-I-reactive T cells was calculated after subtracting
the small percentage of CD154 + CD69 + CD4+ T cells detected within
unstimulated PBMCs from the same subject. Horizontal lines indicate
the mean frequency for each group
Fig. 3 Topoisomerase-I-specific CD4+ T cells activation is HLA-DR
restricted. PBMC from topo-I-positive SSc patients were cultured for 18 h
with topo-I and anti-HLA-DR or anti-HLA-DP blocking antibodies or
isotype control (1 ug/ml). Values are represented as percent of response
relative to the frequency of CD154 + CD69 + CD4+ cells detected after
stimulation with topo-I alone as assessed by flow cytometry. Data are
representative of three separate experiments (mean ± SD)
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Fig. 4 Topoisomerase-I-specific CD4+ T cells show a Th17 polarized functional phenotype. a CD4+ T cell subsets were identified by flow
cytometry using the combined surface expression of chemokine receptors CCR6, CXCR3, and CCR4. b After sorting, the different T helper subsets
were stimulated with anti-CD3/CD28 beads for 48 h and secretion of IFNγ, IL-4, and IL-17A was measured in their supernatants by enzyme-linked
immunosorbent assay (bars represent mean ± SE, n = 3). c The distribution of polarized T helper subsets within topo-I-specific CD4+ T cells (closed
circles) is shown in comparison to the general CD4+ population (open circles). T test with Bonferroni correction was used for multiple comparisons.
Lines indicate mean ± SD. d After sorting topo-I-specific CD4+ T cells according to their polarized T helper phenotype (range 16–2064 cells),
mRNA expression levels of IFNγ, IL-4, and IL-17A were measured by qPCR using the Arcturus® PicoPure® RNA Isolation system, which is designed
to recover high-quality RNA from a very low number of cells (10–500 cells) and to accomplish cDNA synthesis from minimal amounts of cDNA.
IFNγ and IL-17A expression was calculated as fold change in reference to a mix of topo-I-reactive CD4+ T cells from three patients; IL-4 expression
is reported as delta Ct from actin expression since it was not detectable in the reference population. Data are representative of four separate
patients (mean ± SE)
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Therefore, we next addressed these important clinical as-
sociations and sought to define whether the frequency of
topo-I-specific T cell responses might have clinical utility.
Topo-I-reactive T cells were significantly increased in the
peripheral blood of patients with ILD compared to those
without lung involvement (p = 0.002) (Fig. 5a). A lower
DLco was associated with higher number of topo-I-
specific T cells (Pearson r = -0.6, p = 0.018) (Fig. 6) but no
association was found with the FVC (Fig. 5b). In contrast,
the proportion of circulating topo-I-specific CD4+ T cells
was quantitatively associated with the progression of lung
fibrosis as defined by the loss of lung volumes within the
year preceding the test date (Pearson r = 0.721, p = 0.002)
(Fig. 5c) or during the subsequent one (Pearson r = 0.764,
p = 0.017) (Fig. 5d). None of these clinical associations
were found with anti-topo-I serum titers (Additional file 2:
Figure S2). Importantly, the frequency of topo-I-specific T
cells did not show any linear relationship with anti-topo-I
titer or with disease duration (Figs. 7 and 8).These data
suggest that autoreactive T cell activation against topo-I is
sustained during progression of SSc-ILD and predicts
further loss of lung volumes.
Discussion
The evidence that a distinct immune-mediated process
may drive target tissue injury in scleroderma has not
been paralleled by the ability to define with precision its
magnitude and the functional features of involved cel-
lular and molecular effectors. In this study, we have
developed a reliable method to identify and quantify
topoisomerase-I-specific CD4+ T cells with high specifi-
city and precision, determining that in SSc patients
topo-I-specific T cells are strongly polarized toward a
Fig. 5 Frequency of topoisomerase-I-specific CD4+ T cells is associated with presence and progression of interstitial lung disease (ILD). a Frequency of
topo-I reactive CD4+ T cells in anti-topo-I-positive SSc patients stratified by presence of ILD. Lines indicate means. P value was calculated using Wilcoxon
rank-sum test. b Association of topo-I-specific CD4+ T cells with FVC (% predicted). c and d Associations between topo-I-specific CD4+ T cells frequency
and the degree of ILD progression defined as % change in forced vital capacity (FVC) in the year preceding the test date (c) or in the subsequent
10 months (d) in those patients for whom follow-up data became available. Pearson correlation coefficient r and p values are displayed in b, c, and d
Fig. 6 Frequency of topoisomerase-I-specific CD4+ T cells exhibits
negative association with the diffusion capacity of lung for carbon
monoxide (DLco). Association of topo-I-specific CD4+ T cells with
DLco (% predicted) in SSc patients. Pearson correlation coefficient r
and p values are displayed
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pro-inflammatory Th17 phenotype and quantitatively as-
sociated with the presence and progression of ILD.
Lung fibrosis is the most common pulmonary mani-
festation in SSc and a leading cause of morbidity and mor-
tality [25, 26]. A substantial group of SSc-ILD patients
(15–25 %) progress towards end-stage lung disease [27].
Regrettably, treatment options for ILD have been limited
to nonselective immunosuppression. Therapeutic efficacy
has been hindered by our poor ability to diagnose lung in-
volvement earlier, to effectively monitor the disease course
and to identify highly selective pathogenetic targets.
Currently, the only reliable tool to predict disease activity
and progression in SSc-ILD is the prospective measure-
ment of lung volumes, as high-resolution chest computed
tomography or bronchoalveolar lavage fluid analysis have
shown lack of sensitivity and/or specificity both before or
after therapeutic intervention [28, 29]. Importantly, the
fact that ILD progression is often identified by spirometry
criteria only after irreversible lung damage has already oc-
curred remains one of the major obstacles to the prompt
initiation of therapy and ultimately to its efficacy. The
findings of this study indicate that quantification and
functional profiling of topo-I-specific CD4+ T cells may
represent a novel, useful, and noninvasive tool to assess
and predict disease activity in SSc-ILD. Moreover, the
quantitative association of these autoreactive T cells with
the degree of progressive FVC decline suggests that ex-
pansion of the topo-I autoreactive T cells and ongoing
lung injury may be mechanistically connected.
The identification of circulating autoreactive CD4+ T
cells is challenging due to their very low frequency. Previ-
ous studies pursuing the detection of topo-I-specific T
cells in SSc patients have yielded limited results due to
relatively weak cellular responses to topo-I as well as poor
specificity, as autoreactive T cells have been found also in
anti-topo-I-negative patients as well as healthy controls
[12–14, 16]. Most of these investigations used bulk assays
measuring proliferation of mononuclear cells by 3H-thy-
midine incorporation after several days of in vitro stimula-
tion and could not reliably determine the frequency of
circulating topo-I-specific T cells nor provide insight
about their functional phenotype. In addition, these stud-
ies did not yield any data regarding the association be-
tween topo-I-reactive T cells and relevant clinical
outcomes. To overcome these problems, we used full-
length topo-I obtained from a baculovirus-insect cell ex-
pression system and adopted a method that relies on
markers of antigen-driven T cell activation such as CD69
and CD154 [30, 31]. CD154 upregulation is highly specific
for T cell receptor (TCR) engagement with cognate anti-
gens and is not influenced by nonspecific stimuli such as
activating cytokines, providing our study with the specifi-
city and sensitivity needed to detect rare cellular events
[31]. Additionally, CD154 is expressed primarily on CD4+
T cells within few hours, making it the ideal marker to
probe early activation events in response to autoantigen
stimulation [31]. Such early activation is typical of
antigen-experienced cells, which are uniquely and reliably
identified by our method. This provides a clear advantage
over other bulk assays where a significant background
noise may be generated by nonspecific activation of naïve
T cells in response to the culture conditions or topo-I. In
fact, subjects with shared HLA-DR alleles associated with
anti-topo-I antibody positivity may have low-level T cell
clone proliferation in response to the autoantigen [12, 32].
The presence of topo-I specific CD4+ T cells is remark-
ably restricted in our study to patients with anti-topo-I
antibodies. As lung fibrosis may occur in topo-I-negative
Fig. 7 Frequency of topoisomerase-I-specific CD4+ T cells does not
correlate with anti-topoisomerase-I antibody serum concentration.
Serum anti-topoisomerase-I antibody concentration is measured in
units of reactivity compared to a standard low positive sample as
per manufacturer’s instructions. Pearson correlation coefficient r and
p value are displayed
Fig. 8 Frequency of topoisomerase-I-specific CD4+ T cells is not
associated with disease duration. Disease duration is calculated in
years from the first non-Raynaud’s phenomenon symptoms to the
time of blood sampling. Pearson correlation coefficient r and
p values are displayed
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patients, other antigens, known (i.e., U1 RNP, U3 RNP) or
yet unknown, may be targeted and drive the disease
process. Our experimental approach can be applied to
study these other autoantigens as well as to investigate
other rheumatic conditions where the number and func-
tional properties of autoreactive T cells targeting disease-
specific autoantigens may be mechanistically related to
the underlying fibrotic lung disease (i.e., antisynthetase
syndrome).
Anti-topo-I antibodies are class switched, indicating
that topo-I-specific T cells play a significant role in B cell
activation and autoantibody production. However, while
anti-topo-I antibody positivity is strongly associated with
development of SSc-ILD and independently predicts
mortality, serum levels do not correlate reliably with dis-
ease activity and progression [5–10]. This further sug-
gests that T cells may contribute to the pathogenesis of
the disease through their direct pro-inflammatory and
immunomodulatory effect.
We found that CD4 T cell responses to topo-I are
HLA-DR restricted, which confirms and extends previ-
ous reports indicating that anti-topo-I positivity is sig-
nificantly associated with HLA-DRB1*1104 alleles [23].
This finding should further support pursuing the identi-
fication of allele-specific HLA-DR-binding topo-I pep-
tides and the development of tools such as class II
peptide-MHC complexes tetramers, which can enhance
our ability to monitor autoantigen-specific T cell re-
sponses in blood and within target tissues.
Our study shows robustly that topo-I-specific CD4+ T
cells exhibit a chemokine receptor and cytokine expres-
sion profile indicative of a Th17 polarized phenotype.
While the frequency of Th17 lymphocytes is low in the
peripheral blood of healthy individuals, this subset may
undergo recruitment and expansion in sites of active in-
flammation and tissue damage, as shown in several auto-
immune disorders [33–35]. The tight association between
autoreactive T cells and the declining lung function
detected in our SSc-ILD patients suggests a possible
mechanistic link between selective Th17 activation and
progression of lung damage. In animal models, IL-17 can
drive fibrosis, as shown in the lungs and skin of bleomycin
as well as tight-skin-1 (TSK-1/+) mice [36, 37]. In
addition, immunization of C57BL/6 mice with recombin-
ant human topo-I and Freund’s complete adjuvant pro-
motes the development of SSc-like manifestations in
association with increased production of IL-6 and IL-17 as
well as higher levels of circulating IL-17-secreting T cells
(Th17) [38]. IL-17 can also activate TGF-β and CTGC
pathways in fibroblasts derived from mouse skin, and pro-
mote collagen production after epithelial-mesenchymal
transition in mouse alveolar epithelial cells [37]. In con-
trast, a direct Th17-mediated pro-fibrotic function in
humans has not been proven yet. Nonetheless, human
fibroblasts express functional IL-17 receptors and respond
to IL-17 stimulation with activation and proliferation [39].
Skin biopsies obtained from SSc patients have shown in-
creased expression of collagen mRNA in fibroblasts
nearby inflammatory infiltrates and higher numbers of IL-
17+ T cells located in tight proximity of myofibroblasts,
implying a cross-talk between these two cell types [40].
Therefore, Th17 T cell activation may indirectly contribute
to the fibrotic process in SSc by driving early local inflam-
matory events and amplifying the magnitude of fibroblast
response to other direct pro-fibrotic stimuli present in af-
fected tissues. In fact, increased levels of IL-17 and Th17
cells have been found in the peripheral blood as well as
within target tissues of SSc patients during early disease
and in association with ILD [41, 42]. Cytokines crucial for
Th17 T cell priming and expansion such as IL-6 and IL-23
have been reported enriched in SSc subjects [43, 44]. IL-6
secretion by topo I-specific T cell clones has shown to be
crucial for effective activation and production of anti-
topo-I antibodies by autologous B cells obtained by SSc
patients [45]. In addition, polymorphism of the IL-23 re-
ceptor gene (IL23R) has shown association with diffuse
SSc and anti-topo-I positivity [46]. In our previous work,
we have shown that an increased frequency of circulating
Th2/Tc2 polarized T cells in SSc patients is significantly
associated with the presence of pulmonary fibrosis [47].
Other studies have detected a predominance of T cells
producing IFNγ (Th1) both in the periphery and within
affected organs during earlier phases of the disease, with
subsequent decline during late-fibrotic stages [48]. This
emphasizes that the participation of T cells in SSc patho-
genesis may not be exclusively limited to a direct pro-
fibrotic function and varies in terms of intensity and
phenotype during the course of the disease.
Conclusions
Our investigation shows that quantification and functional
profiling of autoantigen-driven immune responses can be
employed to predict with precision the presence and pro-
gression of underlying fibrotic lung disease in SSc. Prospect-
ive studies will determine whether assessing topo-I-specific
T cell responses is useful to measure more precisely the effi-
cacy of therapeutic interventions during routine clinical
care and in experimental trials. More readily, this approach
can be applied to investigate the presence and the function
of autoreactive T cells within target organs, providing im-
portant insight about tissue-specific pathways and mecha-
nisms of injury relevant for SSc onset and progression.
Ethics approval and consent to participate
Patients evaluated at the Johns Hopkins Scleroderma
Center were included in the study after providing writ-
ten informed. The Johns Hopkins institutional review
board approved the study.
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Additional files
Additional file 1: Figure S1. Flow cytometry gating strategy for CD4+ T
cells. G1: live lymphocytes identified in peripheral blood mononuclear cells
(PBMCs) according to the forward and sideward scatters (FSC-A/SSC-A). G2,
G3: singlet selection conducted on FSC-H/FSC-W and SSC-H/SSC-W dot
plots to avoid cellular doublets. G4: dead cells exclusion (Live/Dead Fixable
Blue Dead Cell Stain Kit, Molecular Probes). G5, G6: gating on CD3+ and
CD4+ T lymphocytes. Numbers indicate percentage of parent population.
(TIF 12577 kb)
Additional file 2: Figure S2. Serum levels of anti-topo-I antibodies are
not associated with severity and progression of ILD. (A and B) Association of
anti-topo-I antibodies serum concentration with FVC (% predicted) and
DLco (% predicted). (C and D) Associations between anti-topo-I antibodies
serum levels and degree of ILD progression defined as % change in forced
vital capacity (FVC) in the year preceding the test date (C) and in the
subsequent 10 months (D). Pearson correlation coefficient r and p values are
displayed. (TIF 12770 kb)
Abbreviations
ANOVA: analysis of variance; DLco: diffusion capacity of lung for carbon
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PBMC: peripheral blood mononuclear cells; PCR: polymerase chain reaction;
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SSc: systemic sclerosis; TCR: T cell receptor; Th: T helper; topo-I: anti-
topoisomerase-I; TT: tetanus toxoid.
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